Dr. Timothy Hanna is a clinician scientist at the Division of Cancer Care and Epidemiology, Cancer Research Institute at Queen’s University, and an Adjunct Scientist at ICES. He is also a radiation oncologist at the Cancer Centre of Southeastern Ontario. His work focuses on health services research in oncology, with three translational streams: quality of care, value of care and access to care. His value of care research touches on health technology assessment in the real-world, particularly for novel therapies (e.g. radiotherapy, ‘omics driven personalized medicine, immunotherapy). Methods include machine learning approaches, and often use large, complex administrative data sets.
Dr. Hanna received his PhD and Fellowship training at the Collaboration for Cancer Outcomes Research and Evaluation (CCORE) at Liverpool Hospital in Sydney, Australia (2010-2012). He developed models of population benefit of optimal radiotherapy utilization as part of his PhD thesis work and fellowship there, working with Prof M Barton, Prof G Delaney and Dr. J Shafiq. Prior to this, he trained at Queen’s University in Radiation Oncology and completed an MSc with Dr. WJ Mackillop, focusing on barriers to access to radiation and its impact on cancer outcomes for endometrial cancer. Dr. Hanna obtained his MD at the University of Toronto.
Research Interests
Cancer health services research; access to cancer therapy, quality of cancer therapy; population-based phase IV trials of cancer therapy; global health and oncology; population-based models for cancer service planning, administrative data methods
Research in Progress
Real world outcomes and cost-effectiveness of gene panel testing in Ontario; real world outcomes and cost-effectiveness of innovative drugs for melanoma in Ontario; impact of diagnostic delay and treatment delay on cancer care and cancer outcomes; value of care in radiation oncology
Research Network/Group Involvement
ICES; Terry Fox Marathon of Hope Cancer Centres Network; Ontario Health Cancer Care Ontario Skin Cancers Advisory Committee; Canadian Network for Learning Healthcare Systems and Cost-effective 'Omics Innovation (CLEO); Canadian Cancer Trials Group Committee on Economic Analysis